Advertisement
Not all coronary calcium is the same, analysis shows
Efficacy and safety end points met in 90 percent of patients
Emerging therapies act by neprilysin inhibition and heart rate reduction
A new option for patients who need more than statins
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
One of the largest-ever device trials will assess antibiotic delivery system
Allergic reactions doom factor IXa inhibitor and antidote
Amount of HDL may be less important than previously thought
A novel approach to EVAR aims to reduce risks
Advertisement
Advertisement